Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
All voices matter
biotechnology
Chinese AI biotech deals hit $75B as US scrutiny grows
Chinese biotech firms powered by artificial intelligence have struck out-licensing deals worth $75 billion in the first five months of 2026, a figure that stood at zero before 2020, underscoring how rapidly China has emerged as a global hub for…
Scientists build synthetic cell from scratch for first time
Researchers at the University of Minnesota Twin Cities have created SpudCell, a synthetic cell assembled entirely from non-living chemical components that can feed, grow, replicate its genome, and divide — a first in the decades-long quest to build life in…
Anthropic launches its own drug discovery program for neglected diseases
Anthropic on Tuesday unveiled Claude Science, an AI research workbench for scientists, while simultaneously announcing it will pursue its own preclinical drug discovery programs targeting neglected diseases — areas that traditional pharmaceutical companies have historically avoided.
Anthropic launches Claude Science workbench for researchers
Anthropic on Tuesday began rolling out Claude Science, an AI-powered workbench designed to give scientists a single environment for research across biology, chemistry, genomics, and drug discovery. The product was announced at "The Briefing: AI for Science," a live event…
Penn researchers use AI to find new CAR T therapy targets
Researchers at Penn Medicine have developed an artificial intelligence framework that combines large language models with human scientific expertise to systematically discover new targets for CAR T cell therapy, publishing their findings Wednesday in the journal Cell.
Cambridge team uses base editing to study gene function in human embryos for first time
Researchers at the University of Cambridge have used base editing for the first time to study gene function in human embryos, demonstrating that the NANOG gene is essential for the formation of pluripotent cells during the earliest days of development.…
China approves world’s first CAR-T therapy for solid tumors
China's National Medical Products Administration on Monday approved CARsgen Therapeutics' satricabtagene autoleucel, marking the first regulatory approval anywhere in the world for a CAR-T cell therapy targeting solid tumors. The treatment, also known as satri-cel, is indicated for patients with…
Basel researchers build reusable nanorobot with DNA ‘Velcro’
Researchers at the University of Basel in Switzerland have developed a modular nanorobot that uses complementary DNA strands to autonomously snap its components together, a design they liken to a miniature lunar rocket. The system, published in Advanced Functional Materials,…
AI uncovers new antibiotic candidates for drug-resistant gonorrhea
Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University have used deep learning to identify new antibiotic compounds effective against multi-drug resistant Neisseria gonorrhoeae, according to a study published Wednesday in Science Translational Medicine.
Single gene therapy shot extended mouse lifespan by 20%, study finds
A single injection of gene therapy extended the lifespan of elderly mice by more than 20%, according to a study published in Molecular Therapy by researchers at the Universitat Autònoma de Barcelona. The findings mark the first demonstration that a…
T-rex leather handbag goes under the hammer in Paris
A one-of-a-kind luxury handbag made from lab-grown material derived from Tyrannosaurus rex fossils is being auctioned today at the Hôtel Drouot in Paris, with estimates between €300,000 and €500,000 — roughly $347,000 to $578,000.
China’s RNA editing therapy treats muscular dystrophy in global first
A research team from Changping Laboratory and Peking University has published results in the journal Cell showing that a China-developed RNA editing platform successfully treated pediatric patients with Duchenne muscular dystrophy, marking the first clinical application of RNA editing for…
First person treated with cell-rejuvenating gene therapy for glaucoma
Life Biosciences on Monday announced that the first participant has been dosed in its Phase 1 clinical trial of ER-100, a gene therapy designed to reverse cellular aging in patients with vision loss — marking the first time partial epigenetic…
New CRISPR technique destroys cancer cells by shredding their DNA
Scientists have engineered a CRISPR system that selectively destroys cancer cells by shredding their genetic material, offering a potential new weapon against some of the deadliest and most treatment-resistant tumors. The research, published in Nature on June 8, demonstrates that…